Shandong Duanxintang Dayu Pharmaceutical Co., Ltd.
Main products:Rutin,Quercetin
Contact Us
  • Contact Person : Ms. Zhu Jean
  • Company Name : Shandong Duanxintang Dayu Pharmaceutical Co., Ltd.
  • Tel : 86-537-3422110
  • Fax : 86-537-3412369
  • Address : Shandong,Yanzhou,No. 1, Tiebei East Street
  • Country/Region : China
  • Zip : 272100

pharmaceutical grade troxerutin CAS NO: 7085-55-4

pharmaceutical grade troxerutin CAS NO: 7085-55-4
Product Detailed
1)Assay :99.0% 2)CAS NO.: 7085-55-4 3)GMP certificate 4)Stock available

Name: Troxerutin


Assay :99.0%

CAS NO.: 7085-55-4

Molecular Formula: C33H42O19


Molecular Weight: 742.68


Standard: EP 5.3/EP6/DAB1999


Chemical name : 2-[3,4-Bis(2-hydroxyethoxy)phenyl]-5-hydroxy-7-(2-hydroxy-ethoxy)-3-(6-O-a-L-rhamnopyranosyl-b-D-glucopyranosyloxy)-4H-chromen-4-on


Other names:7,3',4'-Tris[O-(2-hydroxyethyl)] rutin; trioxyethylrutin; tri(hydroxyethyl) rutoside


Physical form: Yellowish green powder


Melting point:168~176°C


M. F. & M. W. : C33H42O19


Particle size: 100% pass through 80 mesh


Main peak: ≥80.0%


One peak:≤10.00%


Single peak: ≤5.0%


Ethylene oxide:≤1ppm


Heavy metals: ≤10.0ppm


Loss on drying:≤5.0%


Storage: avoid light, closeness, keep at the cool, dry place


Valid: 24monthes



This product can inhibit platelet aggregation, prevent thrombosis, can cure the vascular injury induced by 5 serotonin or bradykinin, increase the capillary resistance, reduce the capillary permeability, prevent edema caused by the increasement of vascular permeability. It has the significant protective effect to acute ischemic brain injury. Applying

As the treatment of cerebral thrombosis or the sequela due from the cerebral embolism, such as the hemiplegia, aphasia and myocardial infarction syndrome, arteriosclerosis, central retinitis, phlebitis of thrombosis, varicose veins, edema caused by the vascular permeability rising.




Website :

pharmaceutical grade troxerutin CAS NO: 7085-55-4

Copyright Notice @ 2008-2012 ECVERY Limited and/or its subsidiaries and licensors. All rights reserved.